Ibogaine vs. iboga: what’s the difference between the molecule and the traditional plant experience?
Charles Johnston of Nekawa explores traditional iboga, ibogaine HCl, full-spectrum extracts, and the place of spiritual support alongside medical care. This conversation asks what we preserve—and what we may overlook—when a plant tradition becomes a clinical intervention.
Watch for three questions: How does the approach shape the experience? What does “full spectrum” mean? And how can we respect the roots while taking medical safety seriously?
Learn about Nekawa’s approach in Brazil: https://nekawa.com/
Explore the residential program: https://nekawa.com/program
Subscribe for thoughtful conversations about ibogaine, recovery, and integration.
CHAPTERS
00:00 Ibogaine vs. iboga: the missing piece
00:34 Tradition and the medical perspective
00:50 Flood dosing and cumulative dosing
01:40 Introspection and time
02:36 Substance use disorder and cardiac risk
03:30 Ibogaine HCl and full-spectrum extracts
04:26 Expectations, visions, and social media
05:23 Remembering the roots
06:07 Spiritual support alongside medical care
06:39 Nekawa’s approach
07:15 Iboga or ibogaine?
CLINICAL CONTEXT
This interview shares the speaker’s perspective, including hypotheses about dosing and other plant alkaloids. It does not establish that full-spectrum preparations or cumulative dosing are safer or more effective than ibogaine HCl, or that longer experiences repair the brain. Addiction and mental health involve biological, psychological, and social factors; spiritual support can complement evidence-based care. Effective medications exist. Do not stop prescribed treatment based on this video.
Ibogaine can cause serious cardiac complications, including QT prolongation and potentially fatal arrhythmias. Natural origin and traditional use do not remove those risks. Medical screening, medication review, monitoring, and emergency capability matter. This is education, not a dosing guide or individualized medical advice.
RESEARCH & READING
Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36. https://doi.org/10.1080/00952990.2017.1320802
Knuijver, T., et al. (2022). Safety of ibogaine administration in detoxification of opioid-dependent individuals: A descriptive open-label observational study. Addiction, 117(1), 118–128. https://doi.org/10.1111/add.15448
Ona, G., et al. (2022). The adverse events of ibogaine in humans: An updated systematic review of the literature (2015–2020). Psychopharmacology, 239(6), 1977–1987. https://doi.org/10.1007/s00213-021-05964-y
Clinical Guidelines for Ibogaine-Assisted Detoxification: https://ibogaineguidelines.com/
English closed captions are available through YouTube’s CC control.
#Ibogaine #Iboga #Nekawa
source
